EUVIMEDEUVIMED entdecken
Crossref

Integrated aptamer-based DNAzyme motor with pattern recognition for discriminative intracellular uric acid biosensing and high-throughput GLUT9 inhibitor discovery

Shiquan Zheng, Fengxin Zheng, Jiangtao Hao, Zean Zhao, Hanren Chen, Huaze Shao, Yuexin Xu, Ziyi Huang, Jianxin Pang, Lihong Liu

Biosensors and Bioelectronics · 2026

DOI: 10.1016/j.bios.2025.118323 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biosensors and Bioelectronics, 2026. Verfasst von Shiquan Zheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-M…. Hauptthemen laut MEDLINE: Biosensing Techniques, DNA, Catalytic, Aptamers, Nucleotide, Glucose Transport Proteins, Facilitative. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Guangzhou Municipal Science and Technology Bureau, Guangdong Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current cell-based screening methods for Glucose Transporter 9 (GLUT9) inhibitors, including manual patch-clamp (PC) electrophysiology and radioactive tracer assays, are limited by low throughput and reliance on specialized instrumentation. Here, we develop a biosensing platform combining a DNAzyme motor (DM), an aptamer sensor array (ASA) and pattern recognition-based signal processing (implemented via linear discriminant analysis, LDA), termed DM-ASA-LDA, for intracellular UA detection and GLUT9 inhibitor screening. In this system, the DM is constructed by functionalizing gold nanoparticles (AuNPs) with FAM-labeled substrate strands and DNAzymes locked by aptamers (Apts) that bind uric acid (UA) and xanthine (Xan) with varying affinities. Due to the inability of a single Apt to distinguish UA from Xan, an ASA is designed using three distinct Apts, and the resulting fluorescence signals are processed using LDA. Mechanistically, following endocytosis, the DM is internalized into cells. Intracellular UA and Xan then bind to the Apts, triggering conformational changes that unlock the DNAzyme. The activated DNAzyme cleaves FAM-labeled substrates, resulting in signal conversion and amplification. After cell lysis, the FAM fluorescence is detected and processed by LDA, enabling accurate UA quantification. This quantification capability correlates strongly with PC analysis for evaluating the GLUT9 inhibitor isobavachin (r = 0.9207). Using our platform, mangiferin was identified as a potent GLUT9 inhibitor that significantly reduces UA levels in a hyperuricemic mouse model. Implemented on a 96-well plate, this platform provides high throughput screening with operational simplicity, serving as a practical tool for routine GLUT9 inhibitor evaluation in standard laboratory settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosensing TechniquesDNA, CatalyticAptamers, NucleotideGlucose Transport Proteins, FacilitativeUric AcidAnimalsHumansGoldMiceMetal NanoparticlesHigh-Throughput Screening AssaysXanthineDrug Discovery

Stichwörter der Autor:innen

Aptamer sensor arrayCell-based screening assayDNAzyme motorLinear discriminant analysisUrate-lowering drug

Substanzen

DNA, CatalyticAptamers, NucleotideGlucose Transport Proteins, FacilitativeGoldUric AcidSLC2A9 protein, humanXanthine

Autor:innen und Institutionen

  • NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical…

Förderung

  • China Postdoctoral Science Foundation
  • Guangzhou Municipal Science and Technology Bureau
  • Guangdong Provincial Natural Science Foundation
  • National Natural Science Foundation of China
  • Guangzhou Municipal Science and Technology Project
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Zheng, S., Zheng, F., Hao, J., Zhao, Z., Chen, H., Shao, H., Xu, Y., Huang, Z., Pang, J., & Liu, L. (2026). Integrated aptamer-based DNAzyme motor with pattern recognition for discriminative intracellular uric acid biosensing and high-throughput GLUT9 inhibitor discovery. Biosensors and Bioelectronics. https://doi.org/10.1016/j.bios.2025.118323

Vancouver

Zheng S, Zheng F, Hao J, Zhao Z, Chen H, Shao H, et al. Integrated aptamer-based DNAzyme motor with pattern recognition for discriminative intracellular uric acid biosensing and high-throughput GLUT9 inhibitor discovery. Biosensors and Bioelectronics. 2026. doi:10.1016/j.bios.2025.118323

BibTeX
@article{Zheng2026,
  author = {Zheng, Shiquan and Zheng, Fengxin and Hao, Jiangtao and Zhao, Zean and Chen, Hanren and Shao, Huaze and Xu, Yuexin and Huang, Ziyi and Pang, Jianxin and Liu, Lihong},
  title = {Integrated aptamer-based DNAzyme motor with pattern recognition for discriminative intracellular uric acid biosensing and high-throughput GLUT9 inhibitor discovery},
  journal = {Biosensors and Bioelectronics},
  year = {2026},
  doi = {10.1016/j.bios.2025.118323}
}
Kostenlos starten →